Last updated: August 1, 2026
Triglide is a fenofibrate formulation used to reduce triglycerides and treat mixed dyslipidemia. Its clinical value is tied to the fenofibrate active ingredient rather than to a distinct branded development program. The brand has limited commercial relevance because fenofibrate is widely available as a generic in multiple oral formulations. Current market opportunity is concentrated in generic supply, formulation differentiation, adherence, and combination therapy rather than in new Triglide-specific clinical development.
What is Triglide and what active ingredient does it contain?
Triglide contains fenofibrate, a peroxisome proliferator-activated receptor alpha, or PPAR-alpha, agonist. Fenofibrate increases hepatic fatty-acid oxidation and reduces very-low-density lipoprotein production. It lowers triglycerides and can increase high-density lipoprotein cholesterol.
| Attribute |
Triglide |
| Active ingredient |
Fenofibrate |
| Drug class |
Fibrate lipid-modifying agent |
| Route |
Oral |
| Dosage form |
Film-coated tablet |
| Primary use |
Hypertriglyceridemia and mixed dyslipidemia |
| Mechanism |
PPAR-alpha agonism |
| Regulatory pathway |
FDA-approved prescription drug |
| Commercial category |
Mature branded/generic product |
| Main competitors |
Generic fenofibrate, Tricor, Lipofen, Fenoglide, Antara, fenofibric acid products |
Triglide should be distinguished from Trilipix, which contains fenofibric acid rather than fenofibrate. Fenofibrate products differ in particle size, formulation technology, bioavailability, and food requirements. These differences can affect substitution, prescribing, and payer coverage.
What is the FDA regulatory status of Triglide?
Fenofibrate is an FDA-approved therapy for severe hypertriglyceridemia and selected lipid disorders. Its labeling includes dietary treatment and cautions regarding renal impairment, hepatic disease, gallbladder disease, and drug interactions.
The principal regulatory issues are:
- Dose selection based on renal function.
- Monitoring of serum creatinine and liver function.
- Increased myopathy risk when combined with statins, particularly in patients with renal impairment.
- Increased risk of cholelithiasis.
- Limited cardiovascular-outcome evidence compared with statins.
- Need to evaluate secondary causes of dyslipidemia.
Fenofibrate is generally used as an adjunct to diet and is not a replacement for statin therapy when low-density lipoprotein cholesterol reduction is the primary objective.
What is the Orange Book status of Triglide?
Triglide’s commercial protection is materially weaker than that of an active, patent-protected branded medicine. Fenofibrate has been marketed for decades, and multiple generic products are approved in the United States. The relevant competitive barriers are manufacturing, formulation equivalence, supplier reliability, and pharmacy contracting rather than broad compound patent protection.
The principal Orange Book considerations are:
| Issue |
Market effect |
| Active ingredient patent |
No meaningful current compound exclusivity for fenofibrate |
| Brand exclusivity |
Expired or commercially inactive |
| Generic approvals |
Multiple approved fenofibrate products |
| Paragraph IV exposure |
More relevant historically than to current market entry |
| Orange Book patents |
Product-specific listings must be checked by NDA and dosage form |
| Substitution |
Depends on FDA-rated therapeutic equivalence and formulation requirements |
What clinical trials support fenofibrate?
There is no major ongoing clinical development program unique to the Triglide brand. The relevant evidence base consists of fenofibrate trials and postmarketing studies involving various formulations.
FIELD trial
The Fenofibrate Intervention and Event Lowering in Diabetes, or FIELD, study evaluated fenofibrate in patients with type 2 diabetes who were not routinely receiving statin therapy at baseline. Fenofibrate reduced nonfatal myocardial infarction but did not produce a statistically significant reduction in the primary composite endpoint of coronary events. It reduced some microvascular outcomes, including progression of albuminuria and the need for laser treatment for diabetic retinopathy in selected analyses.
The FIELD results supported use in selected patients with diabetic dyslipidemia but did not establish fenofibrate as a broad substitute for statin therapy.
ACCORD-Lipid
ACCORD-Lipid evaluated fenofibrate combined with simvastatin versus simvastatin alone in patients with type 2 diabetes. The overall study did not show a statistically significant reduction in major cardiovascular events for the combination therapy.
A prespecified subgroup with elevated triglycerides and low HDL cholesterol showed a more favorable treatment effect. That subgroup has influenced clinical use, but the result does not support routine addition of fenofibrate to statin therapy for all patients.
PROMINENT
PROMINENT evaluated pemafibrate, a selective PPAR-alpha modulator, in patients with type 2 diabetes, elevated triglycerides, and low HDL cholesterol who were receiving statin therapy. The trial failed to reduce cardiovascular events despite improving triglyceride-related biomarkers.
PROMINENT reduced expectations that triglyceride lowering alone would produce cardiovascular benefit. The result increases the commercial importance of clinical positioning, patient selection, and guideline alignment for fenofibrate products.
Current clinical-trial outlook
Future fenofibrate research is more likely to focus on:
- Severe hypertriglyceridemia and pancreatitis risk.
- Diabetic retinopathy and kidney disease.
- Residual dyslipidemia after statin treatment.
- Fixed-dose or combination lipid-lowering products.
- Real-world comparative effectiveness.
- Formulations designed to reduce food dependence or improve tolerability.
A large cardiovascular-outcome trial designed to establish broad incremental benefit over optimized statin therapy would face substantial commercial and evidentiary hurdles.
How effective is Triglide compared with statins and newer triglyceride drugs?
Fenofibrate and statins address different lipid priorities.
| Therapy |
Main lipid effect |
Cardiovascular evidence |
Commercial position |
| Fenofibrate |
Strong triglyceride reduction; modest HDL increase |
Mixed, with possible benefit in selected dyslipidemia subgroups |
Low-cost generic |
| Statins |
Strong LDL-C reduction |
Extensive outcome evidence |
Dominant foundational therapy |
| Icosapent ethyl |
Triglyceride reduction with outcome benefit in selected patients |
Positive outcome evidence in REDUCE-IT |
Branded and generic competition |
| Pemafibrate |
Triglyceride reduction |
PROMINENT failed to reduce events |
Limited commercial role |
| PCSK9 inhibitors |
Major LDL-C reduction |
Strong outcome evidence |
High-cost specialty products |
| Bempedoic acid |
LDL-C reduction |
Outcome benefit in statin-intolerant patients |
Branded combination and standalone products |
Fenofibrate remains clinically relevant when triglycerides are very high, when mixed dyslipidemia persists, or when a clinician is targeting the high-triglyceride, low-HDL phenotype. It has a weaker position for general cardiovascular risk reduction than statins and icosapent ethyl in their labeled populations.
When does Triglide lose exclusivity and what generic entry risks exist?
Fenofibrate’s core exclusivity expired years ago. The product faces mature generic competition rather than an imminent first-wave generic-entry event.
Generic entry risks are therefore structural:
- Price erosion. Multiple approved manufacturers pressure average selling prices.
- Formulation substitution. Products with different bioavailability profiles may not be directly interchangeable without regulatory equivalence.
- Supply disruption. Low-margin generic manufacturing can produce shortages or supplier exits.
- Contract concentration. Large wholesalers, pharmacy benefit managers, and Medicaid programs can shift volume rapidly.
- Prescribing substitution. Clinicians may move patients to other fenofibrate dosage forms or fenofibric acid products.
- Therapeutic substitution. Patients may receive statins, icosapent ethyl, or other triglyceride-lowering agents.
A manufacturer seeking to preserve pricing would need a formulation, delivery, adherence, or supply-chain advantage. A conventional immediate-release or standard tablet provides limited protection against generic erosion.
What formulations are protected or commercially differentiated?
Fenofibrate has been commercialized in several formulation types:
- Standard tablets.
- Micronized capsules or tablets.
- Nanocrystal or microcoated formulations.
- Low-dose and high-dose tablets.
- Products with reduced dependence on dietary fat for absorption.
- Fixed-dose combinations with statins in some markets.
Formulation differences can affect bioequivalence, dosing instructions, and food effects. These differences historically supported product-specific patenting and regulatory strategies, but they do not recreate the exclusivity associated with a new chemical entity.
The most commercially defensible formulation opportunities are:
- Consistent exposure under fasting conditions.
- Lower pill burden.
- Combination products.
- Improved renal-dose flexibility.
- Reduced gastrointestinal intolerance.
- Co-packaged treatment for mixed dyslipidemia.
- Manufacturing processes that lower cost while preserving bioequivalence.
How strong is the patent estate for Triglide?
The Triglide patent estate is weak as a current barrier to generic competition. Fenofibrate’s basic active-ingredient protection is expired, and the market has numerous generic and branded-generic alternatives.
| Patent category |
Current strategic value |
| Fenofibrate compound patents |
Expired |
| Original formulation patents |
Generally expired or commercially immaterial |
| Micronization and particle-size patents |
Historically important; limited current blocking power |
| Manufacturing-process patents |
Potentially relevant to cost and supply, but difficult to enforce against all suppliers |
| Method-of-use patents |
Narrow value because fenofibrate uses are established |
| Combination-product patents |
Potentially relevant for new fixed-dose products |
| Delivery-system patents |
Relevant only if linked to a clinically meaningful formulation advantage |
Method-of-use claims may offer limited protection in jurisdictions where skinny-label or indication carve-out strategies are available. Their practical value is reduced by the broad established use of fenofibrate and the availability of generic substitution.
What patent litigation and Paragraph IV challenges affect Triglide?
Triglide is not associated with a current high-value litigation cycle comparable to a recently approved specialty medicine. Historical litigation involving fenofibrate products generally centered on formulation patents, bioequivalence, and generic approval timing.
Paragraph IV risk has primarily applied to:
- Generic challenges against branded fenofibrate products.
- Micronized or bioavailability-enhanced formulations.
- Product-specific patents listed for individual dosage forms.
- Formulation patents covering food-effect or absorption characteristics.
For current commercial planning, the key legal question is not whether a new Paragraph IV challenge will launch against Triglide. It is whether any surviving formulation or process patent can materially restrict supply from approved generic manufacturers. In a mature fenofibrate market, that risk is generally limited.
Which companies compete with Triglide?
Competition is fragmented across generic manufacturers, branded-generic suppliers, and alternative lipid therapies.
Fenofibrate suppliers
Relevant suppliers have included large generic manufacturers such as:
- Teva Pharmaceutical Industries.
- Mylan, now part of Viatris.
- Dr. Reddy’s Laboratories.
- Cipla.
- Lupin.
- Sun Pharmaceutical Industries.
- Zydus Lifesciences.
- Hikma Pharmaceuticals.
- Apotex.
- Amneal Pharmaceuticals.
The exact active supplier set varies by dosage strength, national market, FDA approval status, wholesaler contracts, and product availability.
Therapeutic competitors
Triglide also competes with:
- Generic atorvastatin and rosuvastatin.
- Generic gemfibrozil.
- Fenofibric acid products.
- Icosapent ethyl.
- Prescription omega-3 products.
- Bempedoic acid combinations.
- PCSK9 inhibitors for LDL-focused treatment.
The competitive threat is highest when physicians prioritize LDL-C reduction or when payers prefer statins and low-cost generic alternatives.
What is the market outlook and revenue projection for Triglide?
Standalone Triglide revenue is unlikely to represent a significant growth asset. The brand operates in a mature category with generic substitution, limited promotional support, and low average prices.
A reasonable commercial projection is:
| Period |
Expected market condition |
Revenue direction |
| 2024-2025 |
Mature generic market; limited brand expansion |
Flat to declining |
| 2026-2028 |
Continued price pressure and substitution |
Low-single-digit annual decline likely |
| 2029-2031 |
Stable demand for severe hypertriglyceridemia, but generic erosion persists |
Volume stable; value under pressure |
| Beyond 2031 |
Demand tied to metabolic disease prevalence and treatment guidelines |
Low growth in units; limited branded value |
The broader fenofibrate market may retain unit demand because obesity, diabetes, metabolic syndrome, and severe hypertriglyceridemia remain prevalent. Revenue growth is constrained by generic pricing. Market expansion would require a new formulation, a clinically differentiated combination, or evidence supporting a defined outcome benefit.
Revenue exposure by market segment
| Segment |
Outlook |
| Original Triglide brand |
Limited |
| Generic fenofibrate tablets |
Stable volume, low pricing |
| Micronized or bioavailability-enhanced products |
Moderate differentiation |
| Combination lipid products |
Higher strategic value |
| Severe hypertriglyceridemia |
Durable clinical demand |
| Broad cardiovascular prevention |
Constrained by mixed outcome evidence |
What manufacturing and intellectual-property barriers remain?
Manufacturing barriers are more important than compound patents. Fenofibrate suppliers must manage:
- Particle-size control.
- Uniformity of dosage units.
- Dissolution performance.
- Bioequivalence requirements.
- Stability and impurity control.
- Reliable active pharmaceutical ingredient sourcing.
- Regulatory compliance across manufacturing sites.
- Batch-to-batch consistency.
For generic manufacturers, the principal advantage is scale and cost. For a new entrant, the main barriers are regulatory approval, validated formulation performance, commercial contracting, and reliable supply rather than patent exclusivity.
What are the likely generic launch scenarios?
Three scenarios define the current market.
Base case
Generic fenofibrate remains widely available. Prices continue to decline gradually, while unit demand remains relatively stable. Triglide has limited ability to regain share without a new commercial strategy.
Downside case
Additional suppliers enter, payer reimbursement falls, and prescribers shift patients to statins, icosapent ethyl, or alternative fenofibrate formulations. Brand revenue declines faster than market volume.
Upside case
Demand rises in severe hypertriglyceridemia and selected diabetic dyslipidemia populations. A differentiated formulation or combination product captures value, although the upside applies to the product category rather than to legacy Triglide alone.
Key Takeaways
- Triglide is a fenofibrate product in a mature, heavily genericized market.
- Its clinical evidence derives from fenofibrate trials, especially FIELD and ACCORD-Lipid, not from a distinct Triglide development program.
- Fenofibrate remains useful for severe hypertriglyceridemia and selected mixed-dyslipidemia patients.
- Statins remain the foundation for LDL-C reduction and broad cardiovascular prevention.
- The overall cardiovascular-outcome evidence for routine fenofibrate add-on therapy is mixed.
- Core fenofibrate exclusivity has expired, leaving formulation, process, supply, and combination-product strategies as the main sources of differentiation.
- Current commercial risk is generic price erosion, substitution, and supplier competition.
- Standalone Triglide revenue has limited growth potential without a new formulation, combination, or outcome-based indication.
Frequently Asked Questions
Is Triglide the same as fenofibrate?
Yes. Triglide is a brand formulation containing fenofibrate. Products can differ in strength, particle size, formulation technology, and food-effect instructions.
Is Triglide stronger than generic fenofibrate?
Not inherently. Strength depends on the prescribed dose and formulation. FDA-rated therapeutically equivalent generics are expected to provide comparable clinical performance when used as labeled.
Can Triglide be combined with a statin?
Fenofibrate may be combined with a statin in selected patients, but the combination requires attention to muscle toxicity, renal function, liver function, and drug interactions.
Does fenofibrate reduce cardiovascular mortality?
Fenofibrate has not demonstrated the broad cardiovascular-outcome benefit established for statins. Benefit may be more likely in patients with high triglycerides and low HDL cholesterol, but routine use for all statin-treated patients is not supported by the major outcome trials.
Is there a biosimilar risk to Triglide?
No. Triglide is a small-molecule drug, not a biologic. The relevant competition is generic drug entry, therapeutic substitution, and formulation competition.
References
-
U.S. Food and Drug Administration. (n.d.). Triglide (fenofibrate) prescribing information. FDA.
-
U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
Keech, A., Simes, R. J., Barter, P., Best, J., Scott, R., Taskinen, M. R., Forder, P., Pillai, A., Davis, T., Glasziou, P., Drury, P., Kesäniemi, Y. A., Sullivan, D., Hunt, D., Colman, P., d’Emden, M., Whiting, M., Ehnholm, C., Laakso, M., ... FIELD Study Investigators. (2005). Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus. The Lancet, 366(9500), 1849-1861.
-
ACCORD Study Group. (2010). Effects of combination lipid therapy in type 2 diabetes mellitus. The New England Journal of Medicine, 362(17), 1563-1574.
-
Das Pradhan, A., Glynn, R. J., Fruchart, J. C., MacFadyen, J. G., Zaharris, E., Everett, B. M., Campbell, S. E., O’Donoghue, M. L., Aroda, V. R., Sniderman, A. D., Ridker, P. M., & PROMINENT Investigators. (2022). Triglyceride lowering with pemafibrate to reduce cardiovascular risk. The New England Journal of Medicine, 387(21), 1923-1934.
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.
-
National Library of Medicine. (n.d.). ClinicalTrials.gov. U.S. National Library of Medicine.
